Bioporto ASTHOXF 66 EBIT per Share is $-0.03 as of Dec. 2025. GuruFocus rates THOXF with a GF Score™ of 66/100 and a GF Value™ of $0.17. The stock has 3 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, Bioporto AS ranks better than 51.79% on this metric.
Bioporto AS's EBIT per Share for the
three
months ended in Dec. 2025 was $-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.03.
During the past 3 years, the average EBIT per Share Growth Rate was 13.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 11.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -3.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bioporto AS's EBIT per Share or its related term are showing as below:
THOXF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40.2 Med: 8.6 Max: 23.3
Current: 13.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bioporto AS was 23.30% per year. The lowest was -40.20% per year. And the median was 8.60% per year.
THOXF's 3-Year EBIT Growth Rate is ranked better than 51.79% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75
vs THOXF: 13.60
Bioporto AS's EBIT for the
three
months ended in Dec. 2025 was $-2.42 Mil.
Bioporto AS (OTCPK:THOXF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bioporto AS EBIT per Share Related Terms
Bioporto AS EBIT per Share Historical Data
* Premium members only.
The historical data trend for Bioporto AS's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (THOXF) has a EBIT per Share of $-0.03 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #81 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 48.2%.
Is Bioporto AS's EBIT per Share too high?
Bioporto AS's current EBIT per Share is $-0.03. Based on the distribution chart, Bioporto AS ranks #81 out of 168 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bioporto AS has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #81 out of 168 companies for EBIT per Share. This puts Bioporto AS in the upper half of its industry. The industry median EBIT per Share is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current EBIT per Share is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current EBIT per Share of $-0.03. The stock's GF Value™ is $0.17, compared to a current price of $0.15 — trading 12.4% below its estimated fair value. The current EBIT per Share is $-0.03. Bioporto AS's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bioporto AS (THOXF), the current EBIT per Share is $-0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 12.4% below its estimated GF Value™ of $0.17.
Key valuation signals for THOXF:
EBIT per Share: $-0.03
GF Value™: $0.17 vs. price of $0.15 (12.4% below fair value)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score
Get the complete analysis for THOXF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
